The primary objective of this study is to assess the safety and tolerability of 28 day oral administration of BAY85-8501 versus placebo in subjects with non-CF Bronchiectasis (BE).

The secondary objectives are to examine the effect of BAY85-8501 on pulmonary function, biomarkers of inflammation and tissue damage, and the impact on overall health and perceived well-being and to evaluate the pharmacokinetics of BAY85-8501.

Inclusion Criteria:

• Proven and documented diagnosis of non-CF (cystic fibrosis) idiopathic or post-infectious BE (bronchiectasis) by computed tomography (CT) scan [conventional high resolution CT is considered the standard], including 2 or more lobes and dilated airways compatible with BE at initial diagnosis
• Stable pulmonary status as indicated by the forced, expired volume in 1 second (FEV1) percent predicted ≥30% and <90% (post-bronchodilator)
• Stable (i.e., no dose change) regimen of standard BE treatment administered at least for 4 weeks prior to screening
• Cough on most days

Exclusion Criteria:

• Forced, expired volume in 1 second <30% or ≥90% predicted (post-bronchodilator)
• Recent significant hemoptysis (≥300 mL or requiring blood transfusion) in the preceding 4 weeks before screening (and during the screening period)
• Known cystic fibrosis and/or documented chronic bronchial asthma
• Active allergic bronchopulmonary aspergillosis (ABPA)
• Diagnosis of common variable immunodeficiency (CVID)
• Systemic or inhaled antibiotic treatment within 4 weeks prior to screening
• Treatment of an exacerbation within 4 weeks prior to screening
• Systemic corticosteroids at >10 mg/day prednisolone equivalent for >2 weeks within 4 weeks prior to screening